Project Details
Description
A pilot study of CS-1008, a humanized monoclonal antibody targeting death receptor 5, alone or in combination with imatinib mesylate or sunitinib
Status | Finished |
---|---|
Effective start/end date | 9/25/07 → 12/31/10 |
Funding
- DAIICHI SANKYO, INC.